Equities

Coeptis Therapeutics Holdings Inc

COEP:NAQ

Coeptis Therapeutics Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.1851
  • Today's Change0.010 / 5.47%
  • Shares traded284.17k
  • 1 Year change-81.30%
  • Beta-0.8921
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Coeptis Therapeutics Holdings Inc share price to rise to 3.00 in the next year from the last price of 0.1851.
High1,520.7%3.00
Med1,520.7%3.00
Low1,520.7%3.00

Earnings history & estimates in USD

On Aug 16, 2024, Coeptis Therapeutics Holdings Inc reported 2nd quarter 2024 losses of -0.08 per share.
The next earnings announcement is expected on Dec 02, 2024.
Average growth rate+51.35%
Coeptis Therapeutics Holdings Inc reported annual 2023 losses of -0.83 per share on Mar 26, 2024.
Average growth rate+65.56%
More ▼

Revenue history & estimates in USD

Coeptis Therapeutics Holdings Inc did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Coeptis Therapeutics Holdings Inc did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.